139 related articles for article (PubMed ID: 34145944)
41. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
42. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
43. Denosumab for treatment of postmenopausal osteoporosis.
Chitre M; Shechter D; Grauer A
Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
[TBL] [Abstract][Full Text] [Related]
44. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
[TBL] [Abstract][Full Text] [Related]
45. Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia.
Růžičková O; Killinger Z; Kasalický P; Hamilton L; Tyl R; Tomková S; Kalouche-Khalil L
Adv Ther; 2018 Oct; 35(10):1713-1728. PubMed ID: 30191465
[TBL] [Abstract][Full Text] [Related]
46. Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation.
Anastasilakis AD; Evangelatos G; Makras P; Iliopoulos A
Endocrine; 2020 Sep; 69(3):516-518. PubMed ID: 32441026
[TBL] [Abstract][Full Text] [Related]
47. Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
Binkley N; Krueger D; de Papp AE
Osteoporos Int; 2018 Apr; 29(4):999-1002. PubMed ID: 29455249
[TBL] [Abstract][Full Text] [Related]
48. Risk factors for denosumab discontinuation in patients with postmenopausal osteoporosis.
Hattori K; Takahashi N; Kojima T; Imagama S
Mod Rheumatol; 2023 Jul; 33(4):843-850. PubMed ID: 35788363
[TBL] [Abstract][Full Text] [Related]
49. Back pain-related disability and quality of life in patients affected by vertebral fractures: data from baseline characteristics of population enrolled in Denosumab In Real Practice (DIRP).
Moretti A; Gimigliano F; Di Pietro G; Gimigliano R; Iolascon G
Aging Clin Exp Res; 2015 Oct; 27 Suppl 1():S3-9. PubMed ID: 26210371
[TBL] [Abstract][Full Text] [Related]
50. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
Popp AW; Zysset PK; Lippuner K
Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
[TBL] [Abstract][Full Text] [Related]
51. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
52. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
Okubo N; Matsui S; Matsumoto T; Sugimoto T; Hosoi T; Osakabe T; Watanabe K; Takami H; Shiraki M; Nakamura T
Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
[TBL] [Abstract][Full Text] [Related]
53. Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report.
Maugars Y; Guillot P; Glémarec J; Berthelot JM; Le Goff B; Darrieutort-Laffite C
J Med Case Rep; 2020 Aug; 14(1):130. PubMed ID: 32792004
[TBL] [Abstract][Full Text] [Related]
54. [Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them?].
Lamy O; Gonzalez Rodriguez E; Stoll D; Aubry-Rozier B; Livio F
Praxis (Bern 1994); 2018 Jun; 107(12):649-654. PubMed ID: 29871576
[TBL] [Abstract][Full Text] [Related]
55. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
56. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
57. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
58. Hip fractures following denosumab discontinuation: three clinical cases reports.
Sosa Henríquez M; Gómez de Tejada Romero MJ; Escudero-Socorro M; Torregrosa Suau O
J R Soc Med; 2019 Nov; 112(11):472-475. PubMed ID: 31526209
[TBL] [Abstract][Full Text] [Related]
59. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.
Cummings SR; Ferrari S; Eastell R; Gilchrist N; Jensen JB; McClung M; Roux C; Törring O; Valter I; Wang AT; Brown JP
J Bone Miner Res; 2018 Feb; 33(2):190-198. PubMed ID: 29105841
[TBL] [Abstract][Full Text] [Related]
60. [Multiple vertebral fractures after rebound effect of denosumab in postmenopausal woman].
Ricart Torres E
Aten Primaria; 2024 Feb; 56(2):102810. PubMed ID: 37976777
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]